Hsp90 as a therapeutic target in patients with oesophageal carcinoma

Bibliography

• Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52
   PubMed Web of Science ®Google Scholar
• Sykes AJ, Burt PA, Slevin NJ, Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 1998;48:15-21
   PubMedGoogle Scholar
• Panettiere FJ, Leichman LP, Tilchen EJ, Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat Rep 1984;68:1023-4
   PubMedGoogle Scholar
• Ravry MJ, Moore MR, Omura GA, Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1985;69:1457-8
   PubMedGoogle Scholar
• Bleiberg H, Conroy T, Paillot B, Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20
   PubMed Web of Science ®Google Scholar
• Wadler S, Haynes H, Beitler JJ, Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 1996;78:30-4
   PubMedGoogle Scholar
• Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006:CD002092: first published online: 25 January 2006 in Issue 1, 2006. Last assessed as up-to-date: 30 October 2005, doi: 10.1002/14651858.CD002092.pub2
   Google Scholar
• Arnott SJ, Duncan W, Gignoux M. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005:CD001799: published online: 19 October 2005 in Issue 4, 2005. Last assessed as up-to-date: 30 March 2009, doi: 10.1002/14651858.CD001799.pub2
   PubMedGoogle Scholar
• Gebski V, Burmeister B, Smithers BM, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
   PubMed Web of Science ®Google Scholar
• Lordick F, Ott K, Krause B-J, PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805
   PubMed Web of Science ®Google Scholar
• Carolina P, Hagop K, Jorge EC. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009;84:287-93
   PubMedGoogle Scholar
• Zhang M, Boter M, Li K, Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes. EMBO J 2008;27:2789-98
   PubMedGoogle Scholar
• Zhang M, Windheim M, Roe SM, Chaperoned ubiquitylation–crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol Cell 2005;20:525-38
   PubMed Web of Science ®Google Scholar
• Shiau AK, Harris SF, Southworth DR, Structural analysis of E. coli HSP90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006;127:329-40
   PubMed Web of Science ®Google Scholar
• Mclaughlin SH, Smith HW, Jackson SE. Stimulation of the weak ATPase activity of human Hsp90 by a client protein. J Mol Biol 2002;315:787-98
   PubMed Web of Science ®Google Scholar
• Siligardi G, Panaretou B, Meyer P, Regulation of Hsp90 ATPase activity by the Co-chaperone Cdc37p/p50cdc37. J Biol Chem 2002;277:20151-9
   PubMed Web of Science ®Google Scholar
• Martinez-Ruiz A, Villanueva L, Gonzalez De Orduña C, S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci USA 2005;102:8525-30
   PubMed Web of Science ®Google Scholar
• Scroggins BT, Robzyk K, Wang D, An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007;25:151-9
   PubMed Web of Science ®Google Scholar
• Yu X, Guo ZS, Marcu MG, Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13
   PubMed Web of Science ®Google Scholar
• Yang Y, Rao R, Shen J, Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008;68:4833-42
   PubMed Web of Science ®Google Scholar
• Duval M, Boeuf FL, Huot J, Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial no synthase. Mol Biol Cell 2007;18:4659-68
   PubMed Web of Science ®Google Scholar
• Erkeller-Yüksel FM, Isenberg DA, Dhillon VB, Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 1992;5:803-14
   PubMedGoogle Scholar
• Sumizawa T, Igisu H. Release of heat shock proteins from human neuroblastoma cells exposed to acrylamide. J Toxicol Sci 2008;33:117-22
   PubMed Web of Science ®Google Scholar
• Sidera K, Samiotaki M, Yfanti E, Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 2004;279:45379-88
   PubMed Web of Science ®Google Scholar
• Eustace Bk T, Stewart JK, Functional proteomic screens reveal an essential extracellular role for HSP90alpha in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14
   PubMedGoogle Scholar
• Tsutsumi S, Scroggins B, Koga F, A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2007;27:2478-87
   PubMedGoogle Scholar
• Sidera K, Gaitanou M, Stellas D, A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 2008;283:2031-41
   Google Scholar
• Hartson SD, Ottinger EA, Huang W, Modular folding and evidence for phosphorylation-induced stabilization of an HSP90-dependent kinase. J Biol Chem 1998;273:8475-82
   PubMed Web of Science ®Google Scholar
• Yang S, Qu S, Perez-Tores M, Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 2006;66:6990-7
   PubMedGoogle Scholar
• Wrighton KH, Lin X, Feng X-H. Critical regulation of TGFbeta signaling by Hsp90. Proc Natl Acad Sci USA 2008;105:9244-9
   PubMedGoogle Scholar
• Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000;97:10832-7
   PubMed Web of Science ®Google Scholar
• Stancato LF, Chow YH, Hutchison KA, Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 1993;268:21711-6
   PubMed Web of Science ®Google Scholar
• An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000;11:355-60
   PubMedGoogle Scholar
• Kimura Y, Rutherford SL, Miyata Y, Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev 1997;11:1775-85
   PubMed Web of Science ®Google Scholar
• Smith JR, Clarke PA, De Billy E, Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2008;28:157-69
   PubMedGoogle Scholar
• Vaughan CK, Gohlke U, Sobott F, Structure of an Hsp90–Cdc37–Cdk4 Complex. Mol Cell 2006;23:697-707
   PubMed Web of Science ®Google Scholar
• Pashtan I, Tsutsumi S, Wang S, Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell Cycle 2008;7:2936-41
   PubMed Web of Science ®Google Scholar
• Roe SM, Prodromou C, O'brien R, Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6
   PubMed Web of Science ®Google Scholar
• Prodromou C, Roe SM, O'brien R, Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801
   PubMed Web of Science ®Google Scholar
• Smith V, Sausville EA, Camalier RF, Comparison of 17-dimethylaminoethylamino- 17-demethoxy-geldanamycin (17DMAG) and 17-allylamino- 17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-37
   PubMed Web of Science ®Google Scholar
• Sydor JR, Normant E, Pien CS, Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-13
   PubMed Web of Science ®Google Scholar
• Mccollum AK, Teneyck CJ, Stensgard B, P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008;68:7419-27
   PubMed Web of Science ®Google Scholar
• Guo W, Reigan P, Siegel D, Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-15
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60
   PubMed Web of Science ®Google Scholar
• Lundgren K, Zhang H, Brekken J, BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8:921-9
   PubMed Web of Science ®Google Scholar
• Cheung K-MJ, Matthews TP, James K, The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-43
   PubMed Web of Science ®Google Scholar
• Sharp SY, Prodromou C, Boxall K, Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007;6:1198-211
   PubMed Web of Science ®Google Scholar
• Zhang T, Hamza A, Cao X, A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008;7:162-70
   PubMed Web of Science ®Google Scholar
• Marina F, Silvia H, Zocchi MR, Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992;51:613-9
   PubMedGoogle Scholar
• Kamal A, Thao L, Sensintaffar J, A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
   PubMed Web of Science ®Google Scholar
• Shimamura T, Li D, Ji H, Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008;68:5827-38
   PubMedGoogle Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 2009;106:8368-73
   PubMed Web of Science ®Google Scholar
• Kitano H. Cancer robustness: tumour tactics. Nature 2003;426:125
   PubMed Web of Science ®Google Scholar
• Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006;6:1205-14
   PubMed Web of Science ®Google Scholar
• Bagatell R, Gore L, Egorin MJ, Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007;13:1783-8
   PubMed Web of Science ®Google Scholar
• Banerji U, Affolter A, Judson I, BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008;7:737-9
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Reid J, Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Mccollum AK, Ames MM, A Phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Egorin MJ, Eiseman JL, Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007;13:1769-74
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Trump DL, Eiseman JL, Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Blaney SM, Reid JM, A Phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 2007;13:1789-93
   PubMed Web of Science ®Google Scholar
• Solit DB, Osman I, Polsky D, Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 2008;14:8302-7
   PubMed Web of Science ®Google Scholar
• Grem JL, Morrison G, Guo XD, Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93
   PubMed Web of Science ®Google Scholar
• Ronnen EA, Kondagunta GV, Ishill N, A phase II trial of 17-(Allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-6
   PubMed Web of Science ®Google Scholar
• Eiseman JL, Lan J, Lagattuta TF, Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32
   PubMed Web of Science ®Google Scholar
• Smith V, Sausville EA, Camalier RF, Comparison of 17-dimethylaminoethylamino-17- demethoxy-geldanamycin (17DMAG) and 17-allylamino-17- demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-37
   PubMed Web of Science ®Google Scholar
• Shadad FN, Ramanathan RK. 17-dimethylaminoethylamino- 17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a Phase I study. Clin Lymphoma Myeloma 2006;6:500-1
   PubMedGoogle Scholar
• Pacey SC, Wilson R, Walton M, A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J Clin Oncol 2009;27 (Suppl): abstract 3534
   Google Scholar
• Ge J, Normant E, Porter JR, Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49:4606-15
   PubMed Web of Science ®Google Scholar
• Riely GJ, Stoller R, Egorin M, A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. J Clin Oncol 2009;27 (Suppl): abstract 3547
   PubMedGoogle Scholar
• Sequist LV, Gettinger S, Natale R, A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J Clin Oncol 2009;27 (Suppl): abstract 8073
   Google Scholar
• Macrae C, Richardson G, Walker J, Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: results from two independent phase I trials in patients with advanced cancer. J Clin Oncol 2009;27 (Suppl): abstract e14539
   Google Scholar
• Sessa C, Sharma SK, Britten CD, A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2009;27(Suppl): abstract 3532
   Google Scholar
• Ide S, Motwani M, Jensen MR, Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients. J Clin Oncol 2009;27 (Suppl): abstract 3533
   Google Scholar
• Mitsiades CS, Mitsiades NS, Mcmullan CJ, Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100
   PubMed Web of Science ®Google Scholar
• Richardson PG, Chanan-Khan A, Lonial S, Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. J Clin Oncol 2009;27 (Suppl): abstract 8503
   Google Scholar
• Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3:51-60
   PubMed Web of Science ®Google Scholar
• Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7
   PubMed Web of Science ®Google Scholar
• Doak SH, Jenkins GJS, Parry EM, Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus–their association with aneuploidy and neoplastic progression. Mutat Res Fundam Mol Mech Mutagenesis 2004;547:133-44
   PubMedGoogle Scholar
• Ostrowski J, Mikula M, Karczmarski J, Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med 2007;85:733-43
   PubMed Web of Science ®Google Scholar
• Faried A, Sohda M, Nakajima M, Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer 2004;40:2804-11
   PubMed Web of Science ®Google Scholar
• Wu X, Wanders A, Wardega P, Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17- demethoxygeldanamycin. Br J Cancer 2009;100:334-43
   PubMed Web of Science ®Google Scholar
• Burkitt M, Magee C, O'connor D, Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. Mol Carcinog 2007;46:466-75
   PubMed Web of Science ®Google Scholar
• Ogata M, Naito Z, Tanaka S, Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 2000;67:177-85
   PubMedGoogle Scholar
• Pick E, Kluger Y, Giltnane JM, High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67:2932-7
   PubMed Web of Science ®Google Scholar
• Thierry L, Watson RWG, Vincent M, Heat shock proteins HSP27, HSP60, HSP70, and HSP90. Cancer 2003;98:970-7
   PubMedGoogle Scholar
• Li C-F, Huang W-W, Wu J-M, Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 2008;14:7822-31
   Google Scholar
• Liu XL, Xiao B, Yu ZC, Down-regulation of Hsp90 could change cell cycle distribution and increase drug sensitivity of tumor cells. World J Gastroenterol 1999;5:199-208
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Machida H, Kubota N. Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res 2005;46:215-21
   Google Scholar
• Bull EEA, Dote H, Brady KJ, Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin. Clin Cancer Res 2004;10:8077-84
   PubMed Web of Science ®Google Scholar
• Noguchi M, Yu D, Hirayama R, Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Biochem Biophys Res Commun 2006;351:658-63. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9
   PubMed Web of Science ®Google Scholar
• Chang DT, Chapman C, Shen J, Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Am J Clin Oncol 2009;32(4):405-10
   PubMedGoogle Scholar